(1R,2S,3R,5R)-5-hydroxymethyl-3-[6-[1-(isoquinolin-1-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-1,2-diol | 202267-63-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 英文名称: (1R,2S,3R,5R)-5-hydroxymethyl-3-[6-[1-(isoquinolin-1-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-1,2-diol
• 英文别名: (1S,2R,3R,5R)-3-(hydroxymethyl)-5-[6-[[(3S)-1-isoquinolin-1-ylpyrrolidin-3-yl]amino]purin-9-yl]cyclopentane-1,2-diol
• CAS: 202267-63-8
• 化学式: C₂₄H₂₇N₇O₃
• 分子量: 461.523
• InChiKey: XIADLLYGDJUBDF-VFNKJPDQSA-N

物化性质

• 沸点：
  793.6±70.0 °C(predicted)
• 密度：
  1.62±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  132
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• Methods of treating insulin resistance syndrome and diabetes
  申请人：——

  公开号：US20030176390A1

  公开（公告）日：2003-09-18

  This invention is directed to methods of treating insulin resistance syndrome and diabetes in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound derived from adenosine and analogues thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof, or a pharmaceutical composition comprising such compound.

  本发明涉及治疗胰岛素抵抗综合征和糖尿病的方法，包括向需要治疗的患者施用从腺苷和其类似物衍生的化合物的药效量，或其药用盐、药用前药、N-氧化物、水合物或溶剂化合物，或包含该化合物的药物组合物。
• Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1258247A1

  公开（公告）日：2002-11-20

  The invention relates to the use of adenosine compounds described by formula I and certain derivatives thereof for producing a medicine for the treatment of the insulin resistance syndrome and diabetes. In the formula I K is N, N→O, or CH; Q is CH2 or O; R6 is hydrogen, alkyl, allyl, 2-methallyl, 2-butenyl, or cycloalkyl; E is O or S; Y is e.g. hydrogen, alkyl, aralkyl, aryl; n and p are independently 0, 1, 2, or 3, provided that n + p is at least 1; T is e.g hydrogen, alkyl, acyl, thioacyl, halo, carboxyl; R1, R2 and R3 are independently H, alkyl, or cycloalkyl; A is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR'; B is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR"; R' and R" are e.g independently hydrogen, alkyl, aralkyl or carbamoyl.

  本发明涉及式 I 所述腺苷化合物及其某些衍生物用于生产治疗胰岛素抵抗综合征和糖尿病的药物。 及其某些衍生物用于生产治疗胰岛素抵抗综合征和糖尿病的药物。 在式 I 中 K 是 N、N→O 或 CH； Q 是 CH2 或 O； R6 是氢、烷基、烯丙基、2-甲基烯丙基、2-丁烯基或环烷基； E 是 O 或 S； Y 是氢、烷基、芳烷基或芳基； n 和 p 独立地为 0、1、2 或 3，条件是 n + p 至少为 1； T 例如是氢、烷基、酰基、硫代酰基、卤代酰基、羧基； R1、R2 和 R3 独立地是氢、烷基或环烷基； A 是氢、烷基、羟烷基、烷氧基烷基或 OR'； B 是氢、烷基、羟烷基、烷氧基烷基或 OR"； R'和 R "例如独立地为氢、烷基、芳烷基或氨基甲酰基。
• COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES
  申请人：Aventis Pharmaceuticals Products Inc.

  公开号：EP0912520B1

  公开（公告）日：2003-05-07
• ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1404338A1

  公开（公告）日：2004-04-07
• [EN] ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES<br/>[FR] ANALOGUES DE L'ADENOSINE POUR LE TRAITEMENT DU SYNDROME DE RESISTANCE A L'INSULINE ET DU DIABETE
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2002092093A1

  公开（公告）日：2002-11-21

  The invention relates to the use of adenosine compounds described by formula (I) and certain derivatives thereof for producing a medicine for the treatment of the insulin resistance syndrome and diabetes. In formula (I), K is N, NO, or CH; Q is CH2 or O; R6 is hydrogen, alkyl, allyl, 2-methallyl, 2-butenyl, or cycloalkyl; X is (a) or (b); E is O or S; Y is e.g. hydrogen, alkyl, aralkyl, aryl; n and p are independently 0, 1, 2 or 3 provided that n + p is at least 1; T is e.g. hydrogen, alkyl, acyl, thioacyl, halo, carboxyl; R1, R2 and R3 are independently H, alkyl, or cycloalkyl; A is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR'; B is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR'; R' and R' are e.g independently hydrogen, alkyl, aralkyl or carbamoyl.